By G HossainPosted on November 4, 2025Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex’s New Products Dim as Analysts Eye Kidney Portfolio Post navigation One myth about internal audit that is easily disprovedNovo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid